$1.350
-0.533 (-39.46%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de PPCB por análisis de gráficos similares
Alphio's PPCB stock price prediction model matches the current Propanc Biopharma Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.36 (+0.47%). The 1-week path is $1.36 (+0.48%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Propanc Biopharma Inc?
Propanc Biopharma Inc (PPCB) appears to be a good buy right now due to its recent surge of 202.75% after reporting significant tumor growth inhibition of over 90% in advanced pancreatic cancer models. Additionally, the stock has shown a 25% increase over the last five days, indicating positive momentum. However, the main risk is its year-to-date change of -90.55%, suggesting high volatility and potential for further declines if the positive news does not sustain investor interest.
PPCB cerró en $1.35 el Friday, tras bajar -39.46%
Propanc Biopharma Inc (PPCB) last closed at $1.35, losing -39.46%. These facts feed the 1-day and 1-week PPCB price prediction above.
Factores de la previsión
Los factores de la previsión de Propanc Biopharma Inc (PPCB) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de PPCB, ordenadas por similitud.
Análisis de estacionalidad de PPCB
Historically the probability of a positive August return for PPCB is 32.26%. August offers the highest probability of a positive month at 32.26%, while January is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.